GHK-Cu is a copper peptide complex: the tripeptide glycyl-L-histidyl-L-lysine bound to a copper(II) ion, a sequence first isolated from human blood plasma in the 1970s and later found in saliva, urine, and other tissues. The honest bottom line is that the basic biochemistry is well documented (GHK binds copper with high affinity and acts as a physiological copper carrier feeding enzymes involved in collagen cross-linking and antioxidant defense), while the broader effects on tissue repair and inflammation come largely from cell-culture and animal work rather than large human trials. It is best known from wound-healing and cosmetic research and is most often used topically, with regulatory status that varies by use and jurisdiction.
GHK-Cu is a copper-carrying tripeptide whose copper-binding chemistry and collagen-stimulating activity are documented in laboratory and animal studies, while broad human-benefit claims remain supported by early rather than definitive clinical evidence.
The name is a one-letter shorthand for the three amino acids in the peptide chain, and the Cu suffix records the bound metal: GHK-Cu literally describes the glycyl-histidyl-lysine peptide carrying a copper(II) ion. The structural distinction that matters is the metal itself, since the free peptide is a simple flexible chain while the complex is a defined coordination compound whose stability, blue color, and studied biological behavior all derive from the copper it holds.
The histidine imidazole nitrogen is the principal copper anchor, and together with the terminal amino group and a deprotonated peptide nitrogen it holds the copper(II) ion in the square-planar geometry that gives GHK-Cu its characteristic blue color.
GHK was identified through aging research rather than as an engineered drug, which is part of why it draws interest as a naturally occurring molecule. The published account traces it to plasma chemistry that behaved differently in younger versus older donors, and the molecule is generally understood to be released as a fragment from larger proteins during tissue breakdown rather than secreted on its own.
GHK was first isolated from human blood plasma in 1973 by Loren Pickart and is understood to be liberated as a fragment from larger proteins such as collagen rather than secreted as a standalone peptide.
The copper is not incidental to the molecule; a substantial share of the studied tissue-repair activity is attributed to the metal and to how the peptide regulates its availability. The documented logic is that copper is an essential enzyme cofactor but is chemically hazardous when free, so a peptide that delivers it in a bound, controlled form pairs a regulatory signal with a managed supply of a reactive but necessary metal.
GHK binds copper(II) with high affinity and is described in the literature as a physiological shuttle that delivers copper in a controlled, bioavailable form to enzymes including lysyl oxidase, superoxide dismutase, and cytochrome c oxidase.
GHK-Cu is studied as a multi-target signaling molecule rather than a drug with a single receptor, and the most-cited findings sit at the mechanistic and preclinical level rather than at confirmed human pathways. The reported pattern is broad: gene-expression shifts that favor repair, fibroblast stimulation that builds matrix, and modulation of the enzymes that remodel it, with the precise upstream pathways and any specific receptors still an open research question.
GHK-Cu is documented in cell-culture and animal studies as a multi-target signaling molecule that shifts gene expression toward repair, stimulates fibroblast production of collagen and other matrix components, and modulates matrix metalloproteinases, though its specific receptors and upstream pathways remain unresolved in human studies.
In the wound-healing literature GHK-Cu is positioned as a molecule reported to support several phases of repair at once, from tempering early inflammation to driving collagen deposition and new blood-vessel formation later on. The distinction worth holding is between quantity and quality of rebuilt tissue: because copper-dependent cross-linking through lysyl oxidase is part of how new collagen gains tensile strength, a copper-delivering peptide fits naturally into how a wound matures and how scar tissue organizes, though most of this evidence is preclinical rather than human-clinical.
Across animal-model and cell-culture wound studies, GHK-Cu has been reported to attract repair cells, stimulate fibroblast collagen production, support angiogenesis, and improve measures such as closure rate and tissue architecture, with human clinical evidence remaining more limited than the experimental literature.
The age-linked decline in GHK is one of the original reasons the molecule drew research attention, since it tracks alongside the general slowing of repair, thinning of skin, and reduced regenerative capacity seen with aging. What the published figures do not settle is causation: a falling GHK level could drive reduced regeneration, mark broader aging changes, or be some mix of both, so the decline is best read as a motivating rationale for study rather than proof that restoring the peptide reverses aging.
Plasma GHK is reported to fall from roughly 200 nanograms per milliliter in adults in their twenties to about 80 nanograms per milliliter by around age sixty, an age-linked decline that motivated research interest but does not by itself establish that restoring GHK reverses aging.
The evidence base for GHK-Cu is uneven and weighted toward early-stage research, so the regulatory and interpretive reality is that the best-supported claims are narrow. The basic biochemistry (copper binding, and collagen and matrix stimulation in cultured cells along with gene-expression effects) is well grounded, while broader claims about systemic anti-aging, hair regrowth, or disease prevention rest on thinner or more preliminary data and are most accurately framed as supported by laboratory and early clinical evidence rather than as clinically established outcomes.
The strongest evidence for GHK-Cu is its basic biochemistry (copper binding and collagen, matrix, and gene-expression effects in cultured cells and animal models), while claims of systemic anti-aging, hair regrowth, or disease prevention rest on smaller or preliminary studies and are not established by large placebo-controlled human trials.
GHK-Cu is most widely used in topical form, appearing in serums, creams, and other cosmetic preparations valued for a collagen-stimulating profile, with performance that depends heavily on formulation. The route shapes which effects are biologically plausible in the documented record: a topical acts locally on the dermis and epidermis, whereas systemic delivery would expose a much broader range of tissues and carry different safety and regulatory considerations, and the rigor and regulatory standing of non-cosmetic forms vary widely.
GHK-Cu is used most widely as a topical cosmetic acting locally on skin, where its action depends on formulation factors such as copper-complex stability, concentration, and skin penetration, while injectable and other systemic forms carry broader tissue exposure and more variable regulatory standing.
Educational use only. This article describes what the published scientific and clinical literature reports about GHK-Cu. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
